Health Trials

HER2-low or HER2-ultralow

1

Review clinical trials related to HER2-low or HER2-ultralow. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

The primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer.

Participants needed: 220
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Daiichi SankyoUpdated: Jul 14, 2026
Eligibility criteria

Unresectable or metastatic. [+14]

Prior treatment with an anti-HER3 antibody and/or antibody-drug conjugate (ADC)... [+30]

Read more